home-page-logo

From Concept to Clinic
to the Commercial Market.

YOUR RADIOPHARMACEUTICAL DEVELOPMENT PARTNER.

At CPDC we are working with our partners to discover, develop and distribute the next generation of imaging agents and targeted radiotherapeutics for the detection and treatment of human diseases.

What Are Radiopharmaceuticals?

Radiopharmaceuticals are a special class of drugs. They’re sometimes called molecular imaging probes, contrast agents, tracers or radiotherapeutics.

Radiopharmaceuticals contain a radioactive isotope and they are used to both diagnose and treat disease.  Millions of patients receive radiopharmaceuticals annually for a wide variety of medical procedures ranging from the assessment of cardiac function to staging and treatment of cancer.

Two top research organizations join to speed cancer research with molecular probes

Dana-Farber Cancer Institute and the Centre for Probe Development and Commercialization (CPDC) at McMaster University in Hamilton, Ontario, will work together to create novel molecular probes for non-invasive imaging in cancer research, drug development and patient care. The two leading organizations will form an International Probe Development Consortium (IPDC) to enable and support their collaboration.

Do you love radiopharmaceuticals as much as we do?

CPDC is always looking for exceptional people to strengthen our team.

Join Our Team

For more information contact us at: